肝癌关键可变剪接因子LSM4的功能及其分子调控机制研究
批准号:
82072646
项目类别:
面上项目
资助金额:
55.0 万元
负责人:
陈健翔
依托单位:
学科分类:
肿瘤细胞命运
结题年份:
2024
批准年份:
2020
项目状态:
已结题
项目参与者:
陈健翔
中文摘要
肝癌是一种高致死率的恶性肿瘤,异常的RNA可变剪接和肝癌发生发展息息相关。然而,肝癌增殖相关可变剪接因子还有待系统筛选。我们利用CRISPR-Cas9技术对肝癌细胞增殖必需可变剪接因子进行筛选,发现U6剪接体组分LSM4是肝癌增殖最为关键的一个剪接因子。转录组分析表明其通过调控MYO1B24号外显子等靶点可变剪接来发挥促癌功能。本项目拟通过肝癌细胞、小鼠和肝癌组织等模型来评价LSM4及MYO1B剪接变体MYO1B-L和MYO1B-S的表达、定位和生物学功能;利用细胞分子生物学、转录组学和蛋白质组学等技术揭示LSM4和MYO1B-L促肝癌的分子机制,筛选LSM4、MYO1B变体的相互作用蛋白,阐明其调控机制,最终明确LSM4-MYO1B可变剪接信号促肝癌的关键机理。本研究将首次揭示LSM4在肝癌中的重要作用,阐明其促癌机制,为靶向RNA剪接体的小分子抑制剂研发提供理论依据。
英文摘要
Hepatocellular carcinoma (HCC) is an aggressive malignant tumor with the property of high lethality. Aberrant alternative splicing (AS) of RNA is tightly associated with the initiation and progression of HCC. However, currently it is urgently required to systemically identify and characterize the key AS factors-associated with the proliferation of HCC cells. In this study, the CRISPR-Cas9 technology was employed to screen for the essential AS factors for proliferation (ESF) in HCC cells. We found that a component from U6 snRNP spliceosome, the Sm-like protein 4 (LSM4), is potentially the most crucial ESF for HCC cells’ proliferation, and the LSM4-regulated-transcriptome analysis further indicated that LSM4 could modulate the AS of the 24th exon of MYO1B gene to play its oncogenic role. This project aims to investigate the expression, localization and biological function of LSM4 and its potential splicing variants – MYO1B-L and MYO1B-S using the models of HCC cells line, mice xenograft and HCC patients’ tissues. Through employing the methods of molecular molecular biology, transcriptomics and proteomics, we plan to: reveal the molecular mechanisms of LSM4 and MYO1B-L to promote HCC oncogenesis; screen and identify the interactors of LSM4 and the two MYO1B variants and to elucidate their regulatory mechanisms; finally confirm the crucial role of LSM4-MYO1B AS signalling pathway in HCC promotion. This study will, for the first time, reveal the important role of LSM4 in HCC, clarify its oncogenic mechanism, and provide a theoretical basis for the development of small molecule inhibitors targeting the RNA spliceosome.
本项目揭示了剪接体关键蛋白LSM4的促肝癌作用及分子机制。基于CRISPR-Cas9筛选技术,明确了LSM4是肝癌细胞增殖的必需剪接因子;确认其表达与肝癌预后负相关;并分别在体内体外证明了其促肝癌增殖的作用;利用RNA-Seq、RIP-Seq及SILAC等多组学分析,明确了LSM4参与P体及Cajal体组装,即参与RNA的降解和可变剪接;阐明了LSM4通过调控转录相关基因剪接和降解维持转录稳态以及Ras信号进而促进肝癌进程的分子机制。项目组在Nature Communications、Advance Science等期刊发表SCI论文5篇;在本项目基础上申请获得国自然面上项目1项;在国内外进行特邀学术报告3次;培养博士研究生4名,硕士研究生3名。本项目为肝癌的诊疗提供了潜在的靶点,并发现了剪接因子LSM4除了经典的剪接调控作用还有转录调控功能,为后续RNA剪接与转录时空相关调控因子的探索提供一定理论指导意义。
Wnt/LSM7交互调控信号促进肝癌发生发展的机制研究
-
批准号:82372664
-
项目类别:面上项目
-
资助金额:49万元
-
批准年份:2023
-
负责人:陈健翔
-
依托单位:
PRC1/Wnt信号促进肝癌术后复发关键靶点的功能与调控机制研究
-
批准号:LR21H160001
-
项目类别:省市级项目
-
资助金额:0.0万元
-
批准年份:2020
-
负责人:陈健翔
-
依托单位:
SRSF10-SREK1可变剪接信号轴在肝癌形成和发展中的功能及分子机制
-
批准号:81802338
-
项目类别:青年科学基金项目
-
资助金额:23.0万元
-
批准年份:2018
-
负责人:陈健翔
-
依托单位:
国内基金
海外基金